<DOC>
	<DOC>NCT00973115</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of morning versus evening intake of Simvastatin Controlled Release tablet 20mg for 8 weeks in patients with hyperlipidemia. This study will investigate equivalence of the low-density lipoprotein(LDL) cholesterol percent change.</brief_summary>
	<brief_title>Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Aged between 19 and 75 Defined as a fasting 100mg/dl≤ LDL cholesterol &lt;220mg/dl and triglyceride level&lt;400 mg/dl Need drug therapy by NCEP ATP III guideline Signed informed consent Has a hypersensitivity to HMGCoA reductase inhibitor or simvastatin Has a presence or history of alcohol abuse or drug abuse Active gallbladder disease within 12 months Pancreatitis or Hepatic dysfunction (ALT or AST levels &gt; 2XUNL) HbA1c≥ 9% in type 2 diabetes mellitus patients SBP &lt; 90mmHg or &gt; 160mmHg DBP &lt; 50mmHg or &gt; 100mmHg Myocardial infarction or revascularization procedure within 6 months Has significant cardiovascular disease Malignant tumor within 5years Has fibromyalgia, myopathy, rhabdomyolysis or acute myalgia Uric acid level &gt; 9 mg/dl Thyroid stimulating hormone ≥ 2XUNL Active peptic ulcer disease CPK levels &gt; 3XUNL creatinine level &gt; 2 mg/dl Negative pregnancy test for women of childbearing age and agreement to use contraception while on study Had participated other clinical trial within 4 weeks Need systemic administration of corticosteroids intermittently</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>